Amy Elazzouzi - 25 Oct 2024 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Signature
/s/ Conor Kilroy, Attorney-in-fact
Issuer symbol
AURA
Transactions as of
25 Oct 2024
Net transactions value
$0
Form type
3
Filing time
29 Oct 2024, 20:18:53 UTC
Next filing
29 Oct 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AURA Common Stock 39,996 25 Oct 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 2,554 $5.07 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 1,094 $5.48 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 547 $5.48 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 547 $5.21 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 4,744 $2.74 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 1,094 $3.16 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 2,319 $4.25 Direct F1
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 36,496 $5.48 Direct F2
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 31,500 $14.00 Direct F3
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 17,500 $10.18 Direct F4
holding AURA Stock Option (Right to Buy) 25 Oct 2024 Common Stock 26,670 $7.77 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested.
F2 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021, subject to the Reporting Person's continued service as of each such vesting date.
F3 The shares underlying this option vest as follows: 25% of the shares vest on October 28, 2022 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
F4 The shares underlying this option vest as follows: 25% of the shares vest on January 19, 2024 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
F5 The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney